02-(a)-Łi’ì™·Łv-4.11
|
|
- あいぞう ちとく
- 5 years ago
- Views:
Transcription
1 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) ) 2) 3) JA 2 7 1) 2) 3)
2 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr ( ) (79.2%) Staphylococcus aureus Enterococcus faecalis E. faecalis S. aureus Peptostreptococcus spp. Escherichia coli Klebsiella pneumoniae, Pseudomonas aeruginosa P. aeruginosa Enterobacter cloacae, E. coli, K. pneumoniae Bacteroides fragilis group Vancomycin (VCM) ) I 23 MIC2000 II 1) (79.2%) Table (71.8%) (64.7%) (75.0%) (85.6%) (88.5%) 59.1% (14.5%) (10.2%) (1.9%) (Fig. 1)
3 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 15 ) Table Fig. 1. 2) 2001 Table %, 39.8% 18.8% (9.4%) 6 8 (Table 3) Staphylococcus spp. Enterococcus spp. S. aureus 11 E. faecalis 10 S. aureus 27 E. faecalis 34 E. avium 8 S. aureus (MRSA) 65.8% (25/38) (Table 4) P. prevotii, P. micros Peptostreptococcus spp. (Table 5) 56 E. coli 23 K. pneumoniae 6 P. aeruginosa 6 78 P. aeruginosa 22 E. cloacae 14 E. coli 10 K. pneumoniae 9 (Table 6)
4 108( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table Table B. fragilis group ) (Fig. 2) E. coli (Fig. 3) (Fig. 4)
5 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 17 ) Table Table E. faecalis B. fragilis MRSA S. aureus (Fig. 5) MRSA S. aureus 60% (Fig. 6)
6 110( 18 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table Fig. 2.
7 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 19 ) Fig. 3. Fig. 4.
8 112( 20 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Fig. 5. Fig. 6. MRSA
9 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 21 ) 4) Tables 7 25 MIC (1) S. aureus Oxacillin (MPIPC) 39 MIC 2 (Table 7) 10 MIC 0.5 m g/ml mg/ml MRSA Ampicillin (ABPC) 39 MIC 64 m g/ml Arbekacin (ABK) MIC 8 m g/ml 1 4mg/mL 2 Vancomycin (VCM) Teicoplanin (TEIC) MIC 4 m g/ml m g/ml Gentamicin (GM) 28 MIC 0.5 m g/ml mg/ml Clindamycin (CLDM) MIC 0.5 m g/ml m g/ml 24 2 (2) S. epidermidis S. epidermidis 13 MPIPC MIC 8 m g/ml 8 (Table 8) MIC 8 m g/ml MPIPC, Piperacillin (PIPC), Cefepime (CFPM), Fosfomycin (FOM) 8 ABPC Flomoxef (FMOX) 7 Meropenem (MEPM) GM 6 Cefmenoxim (CMX) CLDM 5 Minocycline (MINO) MIC 0.5 m g/ml ABK, VCM Cefotiam (CTM) MIC 4 m g/ml (3) Enterococcus spp. E. faecalis 44 TEIC MIC 1 m g/ml Imipenem (IPM) VCM ABPC MIC 4 m g/ml (Table 9) MEPM PIPC E. avium 10 TEIC MIC 0.5 m g/ml (Table 10) VCM MIC 1 m g/ml E. faecium 7 TEIC MIC 1 m g/ml (Table 11) VCM 2 m g/ml Enterococcus spp. 8 TEIC MIC 1 m g/ml (Table 12) VCM 4 m g/ml (4) Streptococcus spp. Streptococcus spp. 15 IPM ABPC, TEIC, CLDM, MEPM, VCM, FMOX, CFPM (Table 13) (5) E.coli E. coli 34 (ABPC, PIPC) MIC (Table 14) Cefazolin (CEZ) MIC 16 m g/ml 4 MEPM MIC m g/ml Cefozopran (CZOP) IPM m g/ml CFPM Cefpirome (CPR) MIC 0.25 m g/ml (6) K. pneumoniae K. pneumoniae 15
10 114( 22 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 7. Staphylococcus aureus
11 Table 8. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 23 ) Staphylococcus epidermidis
12 116( 24 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 9. Enterococcus faecalis
13 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 25 ) Table 10. Enterococcus avium
14 118( 26 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 11. Enterococcus faecium
15 Table 12. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 27 ) Enterococcus spp
16 120( 28 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 13. Streptococcus spp
17 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 29 ) Table 14. Escherichia coli
18 122( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 15. Klebsiella pneumoniae
19 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 31 ) Table 16. Enterobacter cloacae
20 124( 32 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 17. Morganella morganii
21 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 33 ) Table 18. Pseudomonas aeruginosa
22 126( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 19. Peptostreptococcus prevotii 9 * 2001
23 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 35 ) Table 20. Peptostreptococcus spp. 14 * 2001
24 128( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 21. Bacteroides fragilis group
25 Table 22. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) Bacteroides spp. 2 * 2001
26 130( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 23. Fusobacterium spp. 4 * 2001
27 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 39 ) Table 24. Prevotella spp. 7 * 2001
28 132( 40 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. Table 25. Veillonella spp. 3 * 2001
29 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 41 ) MIC (Table 15) Cefotiam (CTM) MIC 2 m g/ml MEPM MIC mg/ml CRMN MIC mg/ml CZOP, CEPM, IPM AZT MIC 0.25 m g/ml FMOX, CMX CPR MIC 0.5 m g/ml GM MIC 0.5 m g/ml Amikacin (AMK) 2 m g/ml (7) Enterobacter spp. E. cloacae 18 (Table 16) MEPM, IPM, CFPM (11) Bacteroides spp. Bacteroides fragilis group 53 MIC 90 MEPM IPM 1 mg/ml MINO 4 m g/ml, LVFX 8 m g/ml, Sulbactam/Cefoperazone (SBT/CPZ) 16 m g/ml (Table 21) Bacteroides spp. IPM MEPM (Table 22) (12) Fusobacterium spp Fusobacterium spp. 4 (Table 23) (13) Prevottela spp. Prevottela spp. 7 IPM, MEPM (Table 24) (8) Morganella morganii M. morganii 3 CFPM, CPR, LVFX, Aztreonam (AZT), CZOP, LMOX, MEPM (Table 17) (14) Veillonella spp. Veillonella spp. 3 CLDM, ABPC (Table 25) (9) P. aeruginosa P. aeruginosa 28 MIC 90 GM 2 m g/ml AMK, Isepacin (ISP), LVFX 4 mg/ml (Table 18) (10) Peptostreptococcus spp. Peptostreptococcus prevotii 9 MEPM TEIC (Table 19) Peptostreptococcus spp. P. prevotii (Table 20) III ) ,17) B. fragilis B. fragilis group
30 134( 42 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. B. fragilis group 10) E. coli 11), Klebsiella spp. Enterococcus spp. Enterococcus spp., Pseudomonas spp. 12) MRSA Staphylococcus spp ) VCM, ABK TEIC MRSA, Pseudomonas spp. Enterococcus spp ) VCM MIC 4 m g/ml S. aureus 1 S. aureus, S. epidermidis, E. faecalis Enterococcus spp. E. coli CEZ 100mg/mL MIC 10% 11,13 15) P. aeruginosa IPM 50 m g/ml MIC 20% B. fragilis group MIC 100 m g/ml 16 19) Bacteroides spp. Prevotella spp. MRSA E. coli K. pneumoniae CEZ CTM CMZ MRSA Pseudomonas spp. Enterococcus spp. IPM CZOP CAZ VCM ABK VCM, ABK, TEIC 2 E. coli K. pneumoniae P. aeruginosa VCM 1) 1 Jpn. J. Antibiotics 39: , ) 2 Jpn. J. Antibiotics 41: , ) 37: , ) (MRSA) 2: , ) 3: , 1991
31 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 43 ) 6) 4: 43 49, ) MRSA 5: , ) Jpn. J. Antibiotics 47: , ) Jpn. J. Antibiotics 47: , ) 24: 40 45, ) Escherichia coli Jpn. J. Antibiotics 49: , ) Pseudomonas aeruginosa Jpn. J. Antibiotics 49: , ) 1994 Jpn. J. Antibiotics 49: , ) 1995 Jpn. J. Antibiotics 50: , ) 1996 Jpn. J. Antibiotics 52: , ) Bacteroides fragilis group 28: 48 54, ) 29: , ) 30: 36 43, ) 30: , ) 1997 Jpn. J. Antibiotics 53: , ) 1998 Jpn. J. Antibiotics 54: , 2001 BACTERIA ISOLATED FROM SURGICAL INFECTIONS AND ITS SUSCEPTIBILITIES TO ANTIMICROBIAL AGENTS SPECIAL REFERENCES TO BACTERIA ISOLATED BETWEEN APRIL 2001 AND MARCH 2002 NAGAO SHINAGAWA Department of Surgery, Nagoya Midori Municipal Hospital NAOKI AIKAWA and KAZUHIKO SEKINE Department of Emergency and Critical Care Medicine, School of Medicine, Keio University KOICHI HIRATA, TADASHI KATSURAMAKI and MITSUHIRO MUKAIYA The First Department of Surgery, Sapporo Medical University, School of Medicine SHIGETOMI IWAI and KOUMEI KATO The Third Department of Surgery, Nihon University, School of Medicine YASUHIDE USHIJIMA Department of Surgery, Saitama National Hospital TAKESHI SATO Department of Surgery, Surugadai Hospital, Nihon University, School of Medicine
32 136( 44 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. JIRO YURA Digestive Disease Center, Matsunami General Hospital HIRONOBU OHNISHI and TSUNEHIRO MAEDA The Second Department of Surgery, Wakayama Medical School TADAO MANABE, HIROMITSU TAKEYAMA and MASAMITSU HASEGAWA Nagoya City University Graduate School of Medical Sciences, Department of Gastroenterological Surgery MASAAKI TANIGUCHI Department of Surgery, Nagoya City Koseiin Hospital KEIJI MASHITA Department of Surgery, Bisai Hospital SYU ISHIKAWA Department of Surgery, Takahama Municipal Hospital AKIRA MIZUNO Department of Surgery, Inabe Kousei Hospital NORIAKI TANAKA and HIROMI IWAGAKI The First Department of Surgery, Okayama University, School of Medicine SADAYOSHI FUCHIMOTO and FUMIYUKI INOUE Department of Surgery, Fukuyama National Hospital HIDEYUKI KIMURA Department of Surgery, Okayama Saiseikai Hospital EIJI KONAGA and HITOSHI TAKEUCHI Department of Surgery, Iwakuni National Hospital TAIJIRO SUEDA and YOSHIO TAKESUE Department of Surgery, Graduate School of Biomedical Sciences, Hiroshima University HIROAKI KINOSHITA and KEN MORIMOTO The Second Department of Surgery, Osaka City University, School of Medicine TAKASHI YOKOYAMA and EIZO HIYAMA Department of Genaral Medicine, Hiroshima University, School of Medicine MIKIO FUJIMOTO Department of Surgery, Fujiidera Municipal Hospital SEIYO IKEDA and YOICHI YASUNAMI Department of Surgery 1, Fukuoka University, School of Medicine HIROSHI TANIMURA Department of Surgery, Wakayama Rosai Hospital YUMIKO SUZUKI and YUTAKA NAKANE Section of Studies, Tokyo Clinical Research Center Isolated bacteria from infections in general surgery during the period from April 2001 to March 2002 were investigated in a multicenter study in Japan, and the following results were obtained. In this series, four hundred and twenty strains were isolated from 175 (79.2%) of 221 patients with surgical
33 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) infections. One hundred and eighty-six strains were isolated from primary infections, and 234 strains were isolated from postoperative infections. From primary infections, anaerobic Gram-positive bacteria were predominant, while from postoperative infections, aerobic Gram-positive bacteria were predominant. Among aerobic Gram-positive bacteria, although the isolation rate of Staphylococcus aureus was the highest, followed by that of Enterococcus faecalis from primary infections, the isolation rate of E. faecalis was the highest from postoperative infections. Among anaerobic Gram-positive bacteria, the isolation rate of Peptostreptococcus spp. was the highest from both types of infections. Among aerobic Gram-negative bacteria, Escherichia coli was the most predominantly isolated from primary infections, followed by Klebsiella pneumoniae and Pseudomonas aeruginosa in this order, and from postoperative infections, P. aeruginosa was the most predominantly isolated, followed by Enterobacter spp., E. coli and Klebsiella spp. Among anaerobic Gram-negative bacteria, the isolation rate of Bacteroides fragilis group was the highest from both types of infections. The isolation rate of aerobic Gram-negative bacteria from primary infections and that of aerobic Gram-positive bacteria from postoperative infections were high in the last several years. We noticed no vancomycin-resistant Gram-positive cocci.
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
More informationAug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
More informationApr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357
More informationStreptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More information03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
More informationStaphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More informationPCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More information04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More information70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationFeb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
More informationVOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More informationCHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationDec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationCHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationR01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
More informationDIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More information1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More information(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationCHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More informationOct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
More informationCHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
More informationCHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationVOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
More informationスライド タイトルなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More information公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は
More informationVOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
More informationpneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
More informationTable 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
More informationCHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More information日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
More informationMicrosoft PowerPoint .片山(HP用修正).pptx
平成 29 年度 第 1 回三重県感染対策 援ネットワーク研修会 2017/07/09 ( 臨床第 2 講義室 ) 講演 2 アンチバイオグラムの活 アンチバイオグラム作り 使い 独 政法 地域医療機能推進機構 四 市 津医療センター 薬剤科 副薬剤科 歳也 Japan Community Health care Organization (JCHO) Yokkaichi Hazu Medical
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationTable 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More information2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
More informationKey words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
More information表紙PDF作成用/PDF表紙作成用
2008 Vol.50 No.1 Jpn J School Health Jpn J School Health Jpn J School Health Jpn J School Health Hosen Junior High School, Okayama City Notre Dame Seishin University Graduate School Jpn J School Health
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationVOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
More informationTable 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
More information概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More informationTitle 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Citation 泌尿器科紀要 (1992), 38(11): 1215-1223 Issue Date
More informationMIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
More information概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
More informationCHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More informationCHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
More information08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
More information2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1
2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table
More information01-a-”Oı€™JŠY-4.02
Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 105( 1 ) Fosfomycin b- 2004 11 24 fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate
More informationVOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
More information「薬剤耐性菌判定基準」 改定内容
Ver.3.1 Ver.3.2 改訂内容 (2019 年 1 月 ) 改訂対象改訂前改訂後 メチシリン耐性黄色ブドウ球菌 (MRSA) ペニシリン耐性肺炎球菌 (PRSP) 多剤耐性緑膿菌 (MDRP) 多剤耐性アシネトバクター属 (MDRA) 概要 MPIPC が R の Staphylococcus aureus ( または CFX がディスク拡散法で R ) または選択培地で MRSA と確認された菌微量液体希釈法の基準
More informationKey words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
More information浜松地区における耐性菌調査の報告
平成 28 年度浜松地区感染対策地域連携を考える会 2017 年 2 月 22 日 浜松地区 耐性菌サーベイランス報告 浜松医科大学医学部附属病院 感染対策室 概要 平成 19 年 4 月に施行された改正医療法により すべての医療機関において管理者の責任の下で院内感染対策のための体制の確保が義務化されました 本サーベイランスは 静岡県浜松地区 ( 浜松市 湖西市 ) における薬剤耐性菌の分離状況や薬剤感受性の状況を調査し
More informationCHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
More informationTable 1-1. Criteria for evaluation Table 2. Criteria for bacteriological efficacy Table 1-2. Criteria for evaluation Table 3. Reasons for exclusion and drop-out from evaluation (clinical efficacy) Table
More informationuntitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationCHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
More information1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
More information